Literature DB >> 6735963

Diet-controlled blood levels of oltipraz in healthy male subjects.

H M Ali, M M Homeida, S M Sulaiman, J L Bennett.   

Abstract

The bioavailability of the new antischistosomal agent, oltipraz, was examined under three different dietary conditions in seven healthy males. Oltipraz tablets (500 mg) were administered in single doses (25 mg/kg) under fasting conditions, with a low fat meal (less than 5% fat) and a high fat meal (24% fat). The extent and rate of oltipraz bioavailability were significantly increased by concurrent administration of the drug with food, as demonstrated by the increase in the plasma peak concentration, the area under the plasma concentration vs. time curve and the absorption rate constant. The plasma peak concentration was also reached earlier. Oltipraz plasma concentrations, following its administration under fasting conditions, were almost negligible. The likely mechanisms underlining oltipraz-food interaction are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6735963     DOI: 10.1093/jac/13.5.465

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.

Authors:  H J Prochaska; Y Yeh; P Baron; B Polsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

2.  Clinical pharmacology studies of oltipraz--a potential chemopreventive agent.

Authors:  N V Dimitrov; J L Bennett; J McMillan; M Perloff; C M Leece; W Malone
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

3.  Accuracy of the WHO praziquantel dose pole for large-scale community treatment of urogenital schistosomiasis in northern Mozambique: Is it time for an update?

Authors:  Pedro H Gazzinelli-Guimaraes; Neerav Dhanani; Charles H King; Carl H Campbell; Herminio O Aurelio; Josefo Ferro; Rassul Nala; Alan Fenwick; Anna E Phillips
Journal:  PLoS Negl Trop Dis       Date:  2018-11-15

Review 4.  Current Landscape of NRF2 Biomarkers in Clinical Trials.

Authors:  Yoko Yagishita; Tonibelle N Gatbonton-Schwager; Melissa L McCallum; Thomas W Kensler
Journal:  Antioxidants (Basel)       Date:  2020-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.